Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria
Megan S.F. Soon, Damian A. Oyong, Nicholas L. Dooley, Reena Mukhiya, Zuleima Pava, Dean W. Andrew, Jessica R. Loughland, James S. McCarthy, Jo-Anne Chan, James G. Beeson, Christian R. Engwerda, Ashraful Haque, Michelle J. Boyle
Megan S.F. Soon, Damian A. Oyong, Nicholas L. Dooley, Reena Mukhiya, Zuleima Pava, Dean W. Andrew, Jessica R. Loughland, James S. McCarthy, Jo-Anne Chan, James G. Beeson, Christian R. Engwerda, Ashraful Haque, Michelle J. Boyle
View: Text | PDF
Research Article Immunology Infectious disease

Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria

  • Text
  • PDF
Abstract

High-affinity antibody production depends on CD4+ T follicular helper (Tfh) cells. In humans, peripheral blood Tfh cells are heterogenous, as evidenced by differential expression of the chemokine receptors CXCR3 and CCR6, which to date have served to classify 3 subsets, pTfh1, pTfh2, and pTfh17. Although pTfh1 responses dominate during blood-stage Plasmodium infections, a clear association with protective antibody responses remains to be described. We hypothesized that pTfh cells exhibit greater phenotypic and functional heterogeneity than described by CXCR3/CCR6 and that more nuanced pTfh subsets play distinct roles during Plasmodium infection. We mapped pTfh cell heterogeneity in healthy individuals prior to and during controlled human malaria infection (CHMI) using parallel single-cell RNA-Seq and VDJ-Seq. We uncovered 2 pTfh1 subsets or differential phenotypic states, distinguishable by CCR7 expression. Prior to infection, Tfh1-CCR7– cells exhibited higher baseline expression of inflammatory cytokines and genes associated with cytotoxicity. Tfh1-CCR7+ cells had higher germinal center signatures. Indeed, during CHMI, Tfh1-CCR7+, Tfh1-CCR7–, and Tfh2 cells all clonally expanded and became activated. However, only Tfh1-CCR7+ and Tfh2 cells positively associated with protective antibody production. Hence, our data reveal further complexity among human Tfh cells and highlight 2 distinct subsets associated with antibody-mediated immunity to malaria.

Authors

Megan S.F. Soon, Damian A. Oyong, Nicholas L. Dooley, Reena Mukhiya, Zuleima Pava, Dean W. Andrew, Jessica R. Loughland, James S. McCarthy, Jo-Anne Chan, James G. Beeson, Christian R. Engwerda, Ashraful Haque, Michelle J. Boyle

×

Figure 4

Clonal expansion of diverse pTfh cell subsets during malaria infection.

Options: View larger image (or click on image) Download as PowerPoint
Clonal expansion of diverse pTfh cell subsets during malaria infection.
...
(A) pTfh cells (CXCR5+PD1+ nnCD4 T cells) were isolated from individuals (n = 4) during controlled human malaria infection (CHMI) at day 0, 8, 16, and 36. scType label transfer was used to identify Tfh transcriptional subsets using the healthy Tfh cell dataset as a reference. (B) Average expression of marker genes used to annotate reference dataset in each subset in the CHMI dataset. (C) Relative proportion of each pTfh transcriptional cluster during CHMI. Each individual is shown. Wilcox signed-rank test is indicated for comparison between day 0 and day 16; however, these should be interpreted cautiously due to limited sample size in scRNA-Seq data set. (D) Counts of clones with either a clone size = 1 or clone size ≥ 2 across days. Clonal expansion was detected at day 16. (E) Clone family size count over time in each subset. Clonal expansion was detected in Tfh1_CCR7neg, Tfh1_CCR7pos, and Tfh2 clusters at day 16. (F) Simpson’s diversity index in each donor across time. (G) Clonal overlap at day 16 across clusters. Clonal size is indicated in count in top bar, and each clonal proportion across subsets is indicated. See also Supplemental Figures 6 and 7.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts